newsfilter
← Earnings
Earnings Releases·

BioCardia — Third Quarter 2026 Earnings Summary

BioCardia, Inc. reported a net loss of $1.8 million for the third quarter of 2026, with total operating expenses reaching $1.8 million. The company successfully completed regulatory interactions with Japan's PMDA regarding its CardiAMP autologous cell therapy and expects to submit for approval in Japan during late 2026 or early 2027. Additionally, the FDA accepted the company's pre-submission minutes for the Helix transendocardial delivery system, with a full De Novo submission targeted for the first quarter of 2027. BioCardia ended the quarter with $2.2 million in cash and cash equivalents, providing an anticipated runway into 2027.

Company
BIOCARDIA INC
Sector
Healthcare
Industry
Biotechnology